Form 4 Filing for Avalo Therapeutics, Inc.

This filing details a Form 4 filed by Samantha Truex, a director at Avalo Therapeutics, Inc. (AVTX), on June 4, 2026. The report covers transactions on June 2, 2026. Truex acquired 20,100 stock options with a right to buy at a price of $0.00 per share. These options are for Avalo's Common Stock and vest fully on the first anniversary of the grant date, contingent upon continued service. The options have an exercise price of $13.96 and an expiration date of June 2, 2036. The filing indicates direct ownership of these derivative securities.